Table 3. Perioperative outcomes (propensity-matched).
| Study | Year | Approach | n | Valve | Redo | Ventilation (hrs) | ICU LOS (days) | Hospital LOS (days) | Procedure Time (mins) | Valve MG (mmHg) |
|---|---|---|---|---|---|---|---|---|---|---|
| RT | ||||||||||
| Terwelp | 2017 | MiAVR | 115 | NR | NR | 27.1±93 | 2.7±4 | NR | NR | NR |
| TAVI-TA | 115 | NR | NR | 134.2±1 | 3.9±5 | NR | NR | NR | ||
| Terwelp | 2017 | MiAVR | 247 | NR | NR | NR | 2.9±4 | 7.5±5 | NR | NR |
| TAVI-TF | 247 | NR | NR | NR | 2.3±3 | 4.1±4 | NR | NR | ||
| Micelli | 2016 | MiAVR | 37 | Percevel S | NR | NR | 1±0.3 | 7±0.5 | NR | 11.4±3.7 |
| TAVI | 37 | Sapien | NR | NR | 1 | 4.5±0.75 | NR | 10.1±3.4 | ||
| HS | ||||||||||
| Furu-kawa | 2018 | MiAVR | 177 | NR | 1 | 22.5±63 | 3.4±6 | 15.2±8 | NR | 12.0±4.6 |
| TAVI-TA | 177 | NR | 2 | 21.5±67 | 4.7±6 | 18.2±6 | NR | 11.0±7.7 | ||
| TAVI-TF | 177 | NR | 1 | 1.89±22 | 3.3±4 | 12.9±8 | NR | 10.2±5.8 | ||
| Calle-Verda | 2018 | MiAVR | 50 | NR | NR | NR | 2.2±2 | 10.1±7 | 87.2±23a | NR |
| TAVI | 50 | CoreValve | NR | NR | NR | 8.5±4 | NR | NR | ||
| Zierer | 2009 | MiAVR | 30 | Perimount | 0 | NR | 3.2±2 | 12±3 | 208±28 | 7.3±3.7 |
| TAVI | 21 | Cribier | 3 | NR | 1.0±0.4 | 5±1 | 154±33 | 9.6±37 | ||
| COM | ||||||||||
| Paparella | 2019 | MIAVR | 386 | Multiple BioP + mech | 38 | NR | 1.9±0.3 | 8±1 | NR | NR |
| TAVI | 386 | Corevalve, SAPIEN, Lotus | 42 | NR | 1±0.2 | 6±1 | NR | NR |
Continuous data presented as mean ± SD. a, cardiopulmonary bypass time. RT, right anterior thoracotomy; HS, hemi-sternotomy; COM, combined; NR, not reported; Redo, previous sternotomy; ICU, intensive care unit; LOS, length of stay; MG, mean gradient; MiAVR, minimally invasive aortic valve replacement; TAVI-TA, transcatheter aortic valve implantation via trans-apical approach; TAVI-TF, transcatheter aortic valve implantation via trans-femoral approach; BioP, bioprosthetic: mech-mechanical.